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Abstract
Stra13, a basic helix-loop-helix (bHLH) transcription factor is involved in myriad biological functions including cellular
growth arrest, differentiation and senescence. However, the mechanisms by which its transcriptional activity and function
are regulated remain unclear. In this study, we provide evidence that post-translational modification of Stra13 by Small
Ubiquitin-like Modifier (SUMO) dramatically potentiates its ability to transcriptionally repress cyclin D1 and mediate G1 cell
cycle arrest in fibroblast cells. Mutation of SUMO acceptor lysines 159 and 279 located in the C-terminal repression domain
has no impact on nuclear localization; however, it abrogates association with the co-repressor histone deacetylase 1
(HDAC1), attenuates repression of cyclin D1, and prevents Stra13-mediated growth suppression. HDAC1, which promotes
cellular proliferation and cell cycle progression, antagonizes Stra13 sumoylation-dependent growth arrest. Our results
uncover an unidentified regulatory axis between Stra13 and HDAC1 in progression through the G1/S phase of the cell cycle,
and provide new mechanistic insights into regulation of Stra13-mediated transcriptional repression by sumoylation.
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Introduction
Stra13, a member of the bHLH-O repressor subfamily is widely
expressed both during embryonic development as well as in a
number of adult tissues [1,2]. In addition to being constitutively
expressed in several cell types, its expression is up regulated in
response to multiple stimuli including retinoic acid, TGFb, serum
deprivation, genotoxic agents and trichostatin A (TSA). Several
gain of function and loss of function studies have shown its
involvement in cellular differentiation programs, cell cycle
progression, senescence, apoptosis, immune responses, tissue
regeneration and circadian rhythms [3–17]. However, the
molecular mechanisms through which Stra13 regulates these
diverse biological responses are largely unclear. Previous studies
have shown that Stra13 overexpression results in growth
suppression, cell cycle arrest, and cellular senescence, which are
important tumor suppression mechanisms [4,6,10,12,17]. Consis-
tent with these observations, Stra13 expression is indeed down
regulated in some tumors. Intriguingly however, it is also
overexpressed in many cancers [2,18–22]. Similarly, while Stra13
inhibits differentiation of some cell types, it promotes others
[3,8,9]. The seemingly paradoxical functions of Stra13 could
potentially occur by altered sub-cellular localization, or association
with distinct co-factors in different cell types. Alternatively, post-
translational modifications may allow it to rapidly and reversibly
alter functions in diverse cellular contexts.
We and others have previously demonstrated that Stra13
associates with the co-repressor HDAC1 through its C-terminal
repression domain that contains three a-helices [4] and regulates
transcriptional repression of specific target genes [4,23,24].
However the mechanism by which HDAC1 regulates Stra13-
dependent biological functions is unclear.
SUMO (Small Ubiquitin-related Modifier) modification, or
sumoylation, is an important post-translational modification that
modulates the biological functions of proteins [25,26]. Sumoyla-
tion is a highly dynamic process, whereby SUMO is covalently
conjugated to an obligatory lysine in canonical yKXE SUMO
motifs (where y is a hydrophobic amino acid, K is the acceptor
lysine for covalent attachment of SUMO, and X is any residue,
and E is glutamic acid) in the substrate. Sumoylation is a three-step
reaction consisting of SUMO activation, transfer, and ligation that
are catalyzed by E1 heterodimeric enzyme (SAE1/SAE1), E2
enzyme (Ubc9) and E3 SUMO ligases, of which the Protein
Inhibitor of Activated Stats (PIAS) proteins have been well-
characterized [27,28]. Protein sumoylation is readily reversed by
cellular isopeptidases or Sentrin/SUMO-specific proteases (SENP,
SUSP), which cleave SUMO from its substrate. Unlike ubiquitina-
tion, which usually facilitates protein degradation, sumoylation
results in pleiotropic functional consequences that include changes
in subcellular localization, protein stability, alterations in DNA-
binding and transcriptional activity. Transcription factors, co-
activators and co-repressors are predominant targets of sumoyla-
tion, which alters their activity resulting in changes in gene
expression and function [29,30].
In this study, we demonstrate that Stra13 can be SUMO
modified at conserved residues Lys 159 and Lys 279 that is
enhanced by the SUMO E3 ligases PIAS3 and PIAS1. Mutation
of these target residues, or co-expression of the SUMO protease
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SENP1 with wild type Stra13, impairs its ability to repress cyclin
D1 expression and attenuates its function as a growth suppressor.
In addition, mutation of sumoylation sites reduces association of
Stra13 with HDAC1, which plays an essential role in cell cycle
progression. HDAC1 inhibits Stra13 sumoylation in a deacetylase-
activity dependent manner and blocks its anti-proliferative effects.
Together these studies identify sumoylation as a key post-
translational modification that modulates Stra13 transcriptional
repression activity and function in cell cycle arrest.
Results
Stra13 Sumoylation is Enhanced by PIAS3 and PIAS1
We have previously demonstrated that the co-repressor
HDAC1 interacts with the C-terminal region of Stra13 spanning
amino acid residues 111–343 (Fig. 1A; and 4). Alignment of this
region from several species revealed two potential sumoylation
motifs AKHE and IKQE. K279 within the IKQE motif was
phylogenetically conserved, whereas K159 within AKHE was less
conserved through various species (Fig. 1A). To examine whether
Stra13 undergoes sumoylation, we transfected cells with constructs
encoding Myc-Stra13 in the absence or presence of SUMO1.
Lysates were immunoprecipitated with Myc-agarose beads
followed by western blotting with anti-SUMO1 antibody. A
putative sumoylated band was detected in the presence of SUMO1
(Fig. 1B). To examine whether the slower migrating band
corresponds to sumoylated Stra13, we co-transfected the Sen-
trin-specific protease (SENP), which is able to remove SUMO
conjugates from substrates. In the presence of SENP1, sumoyla-
tion was abrogated, confirming that Stra13 is indeed sumoylated
in cells. To examine whether K159 and K279 serve as acceptor
sites for sumoylation, we generated lysine (K) to arginine (R) point
mutants at each site individually (Stra13 K159R and Stra13
K279R respectively) and together (2KR) by site-directed muta-
genesis. Cells were transfected with Stra13, Stra13 K159R, Stra13
K279R as well as the double mutant Stra13 2KR (Fig. 1C).
Immunoprecipitation and western blotting analysis revealed that
in presence of SUMO1, both Stra13 and Stra13 K159R mutant
were sumoylated. In contrast, neither Stra13 K279R, nor Stra13
2KR were sumoylated, suggesting SUMO conjugation occurs
predominantly at K279. The PIAS protein family act as E3
SUMO ligases and enhance sumoylation of target proteins [28].
To examine whether PIAS proteins modulate Stra13 sumoylation,
we co-transfected cells with Myc-Stra13, SUMO1 and Flag-
PIAS1, PIAS3, PIASxa, and PIASy. Cell lysates were immuno-
precipitated with Myc-agarose beads, and analyzed by western
blotting with anti-SUMO1 antibody. Both PIAS3 and PIAS1
enhanced Stra13 sumoylation, whereas expression of PIASxa and
PIASy had a minimal impact (Fig. 1D).
Stra13 Sumoylation is Required for its Anti-proliferative
Effects
Stra13 mediates growth suppression in a number of cell types
and has also been implicated in cellular senescence [4,6,10,12].
We therefore examined whether sumoylation impacts Stra13-
mediated growth arrest. NIH3T3 cells were co-transfected with
Stra13, or Stra13 2KR, along with pD503, which confers
resistance to puromycin. Western blot analysis showed equivalent
expression of Stra13 and Stra13 2KR (Fig. 2A). After selection,
cells were seeded at a low density and analyzed for colony
formation two weeks later. Consistent with our previous studies
[4], overexpression of Stra13 resulted in significant reduction in
colony numbers compared with vector-transfected cells (Fig. 2B,
C). Interestingly, in contrast to wild type Stra13, Stra13 2KR was
unable to inhibit colony formation (Fig. 2B, C). To examine the
underlying mechanisms, we measured proliferation of cells
expressing Stra13 and Stra13 2KR relative to vector controls.
Stra13 overexpressing cells resulted in reduced cell numbers over a
five-day period, whereas Stra13 2KR expressing cells proliferated
similar to control cells (Fig. 2D). Consistently, re-expression of wild
type Stra13 but not Stra13 2KR in mouse embryonic fibroblast
(MEFs) derived from Stra132/2 mice [5] led to growth
suppression (Fig. 2E). We then examined the cell cycle profile of
Stra13 and Stra13 2KR overexpressing cells by flow cytometry
(Fig. 2F). Compared to controls, Stra13 expressing cells exhibited
delayed progression in the G1/S phase of the cell cycle, resulting in
G1 arrest. In contrast, the cell cycle profile of Stra13 2KR cells was
similar to controls. However, expression of either protein had no
impact on the sub-G1 phase. Together these results suggest that
reduced colony formation upon Stra13 overexpression is due to
reduced proliferation rates and G1 arrest rather than increased
apoptosis.
The inability of Stra13 2KR mutant to mediate growth
suppression suggested that sumoylation may be involved in the
anti-proliferative effects of Stra13. To determine the impact of
sumoylation on Stra13-mediated growth inhibition, we asked
whether inhibition of Stra13 sumoylation recapitulates the
phenotype of Stra13 2KR expressing cells. To examine this
possibility, we performed colony assays in cells expressing the
SUMO protease SENP1 along with equivalent levels of Stra13
and Stra13 2KR (Fig. 3A). Co-expression of SENP1 reversed the
anti-proliferative effect of Stra13 whereas, as expected, Stra13
2KR was insensitive to SENP1 (Fig. 3B–C) confirming that
sumoylation of Stra13 is indeed critical in mediating growth arrest
in fibroblast cells.
SUMO Modification of Stra13 does not Affect its
Subcellular Localization but Enhances its Ability to
Repress Cyclin D1
To examine the molecular basis underlying Stra13-mediated G1
arrest, the expression of endogenous cyclin D1 and p21 that
regulate G1/S transition was analyzed by Q-PCR. Stra13
significantly inhibited cyclin D1 expression, and up-regulated the
levels of p21Cip/WAF (Fig. 4A). In contrast, Stra13 2KR expressing
cells did not show a significant change in the expression of either
gene relative to control cells. Cyclin B1 and cyclin E1 expression
was similarly regulated in cells expressing Stra13 and Stra13 2KR.
Since sumoylation typically enhances transcriptional repression,
we examined whether it is required for Stra13-mediated repression
of cyclin D1 expression. A cyclin D1 promoter reporter [31] was
co-expressed with Stra13, SUMO1 and SENP1. Consistent with
repression of endogenous cyclin D1 expression, Stra13 repressed
the cyclin D1 reporter, which was further augmented in presence
of SUMO1, and attenuated in the presence of SENP1 (Fig. 4B).
Stra13 2KR was unable to repress cyclin D1 promoter to the levels
achieved with Stra13, confirming that sumoylation is relevant in
Stra13-mediated repression of cyclin D1 expression. Since
sumoylation can regulate the subcellular localization of target
proteins [25–27], we examined whether the inability of Stra13
2KR to repress cyclin D1 was due to altered cellular localization.
Stra13 and Stra13 2KR transfected cells were immunostained
with anti-Myc antibody, and visualized by confocal microscopy.
Both proteins showed nearly identical patterns of nuclear
localization that was independent of sumoylation sites (Fig. 4C).
Similarly, no differences were apparent between wild type and
Stra13 2KR in the presence of SUMO1. Thus, the inability of
Stra13 2KR to transcriptionally repress cyclin D1 is not due to
altered subcellular localization. To determine whether cyclin D1 is
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directly regulated by Stra13, we performed chromatin immuno-
precipitation (ChIP) assays in NIH3T3 cells that were left
untreated or treated with trichostatin A (TSA) which causes
growth arrest [4]. Binding of endogenous Stra13 was evident on
the cyclin D1 promoter both in the absence and presence of TSA
treatment (Fig. 4D). These findings are consistent with a recent
study [17] demonstrating that cyclin D1 is a Stra13 target gene.
HDAC1 Regulates Stra13 Sumoylation, Cyclin D1
Repression and Growth Arrest
As Stra13 sumoylation sites are located within the HDAC1
interaction region, we tested whether the association between
HDAC1 and Stra13 is SUMO-dependent. Cells were transfected
with Stra13 or Stra13 2KR mutant together with Flag-HDAC1.
Lysates were immunoprecipitated with Myc-agarose beads
followed by western blotting with anti-Flag antibody (Fig. 5A).
As previously reported, Stra13 interacted with HDAC1 [4], and
consistent with a recent report [32], sumoylation-defective Stra13
2KR interacted less efficiently with HDAC1 compared to wild
type Stra13. Several studies have demonstrated that HDACs
modulate sumoylation of proteins. To investigate whether
HDAC1 modulates Stra13 sumoylation, we co-expressed the two
proteins. Interestingly, Stra13 sumoylation was almost completely
abolished by HDAC1. Moreover, TSA (a histone deacetylase
inhibitor) reversed HDAC1-mediated inhibition of Stra13 sumoy-
lation (Fig. 5B). To validate these findings, endogenous Stra13 was
immunoprecipitated from cells in the absence and presence of
TSA treatment. Indeed, Stra13 sumoylation (Fig. 5C), and its
association with HDAC1 (Fig. 5D), was enhanced in TSA treated
cells. To further examine the role of endogenous HDAC1 in
Stra13 sumoylation, its expression was down-regulated with
HDAC1 specific siRNA (siHDAC1). Control cells were transfected
with scrambled siRNA (siRNA). The down-regulation of HDAC1
expression in siHDAC1 cells (Fig. 5E) led to enhanced Stra13
sumoylation compared to controls (Fig. 5F) demonstrating that
endogenous HDAC1 regulates Stra13 sumoylation.
In contrast to the anti-proliferative effect of Stra13, HDAC1 is
known to promote proliferation via regulation of G1/S progres-
sion. Given its impact on sumoylation, we examined whether
HDAC1 antagonizes Stra13-dependent growth suppression that is
sumoylation-dependent. NIH3T3 cells were co-transfected with
equivalent amounts of Stra13 and Stra13 2KR along with
HDAC1 (Fig. 5G). In its presence, Stra13-mediated growth
suppression was abrogated and phenotypically resembled Stra13
2KR cells (Fig. 5H, I). To further investigate whether the loss of
growth suppression occurs due to an impact on cyclin D1, we
performed reporter assays. In presence of HDAC1, repression of
the cyclin D1 promoter by Stra13 and SUMO1 was attenuated in
a dose-dependent manner (Fig. 5J). Conversely, in siHDAC1 cells,
Stra13-mediated repression of cyclin D1 was augmented com-
pared to controls (Fig. 5K) Together, these results demonstrate
that HDAC1 inhibits Stra13 sumoylation, and consequently its
ability to repress cyclin D1 that is essential for growth suppression
in fibroblast cells.
Discussion
In this study we have identified sumoylation as a key
modification that impacts Stra13-mediated transcriptional repres-
Figure 1. Stra13 is sumoylated. (A) Schematic representation of the Stra13 domain structure (upper panel). The basic and HLH domains are
shown along with three a-helices in the C-terminal repression domain. Potential sumoylation acceptor lysines at 159 and 279 (K159 and K279) are
indicated. Numbers indicate amino acid residues in the mouse Stra13 cDNA. Alignment of Stra13 cDNA from various species revealed a highly
conserved SUMO consensus motif IKQE, and a somewhat less conserved motif AKHE that are highlighted. K159 and K279 are indicated by arrowheads
(lower panel). (B) Cells were co-transfected with Myc-Stra13, SUMO1 and SENP1 as indicated. Lysates were immunoprecipitated with Myc-agarose
beads followed by immunoblotting with anti-SUMO1 antibody. Input shows expression of Stra13 using anti-Myc antibody. b-actin served as a loading
control. (C) Cells were co-transfected with Myc-Stra13, or point mutants (Stra13 K279R, Stra13 K159R, Stra13 2KR) together with SUMO1. Cell lysates
were immunoprecipitated with Myc-agarose beads and the immunoprecipitates were subjected to western blotting with anti-SUMO1 antibody.
(D) Myc-Stra13 and SUMO1 were expressed along with Flag-PIAS1, PIAS3, PIASxa, or PIASy as indicated. Lysates were immunoprecipitated with Myc-
agarose beads followed by western blotting with anti-SUMO1 antibody. Lysates (input) were probed for Stra13 and PIAS.
doi:10.1371/journal.pone.0043137.g001
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sion with an overt impact on its function in cell cycle arrest.
Mutation of sumoylation sites attenuates the anti-proliferative
effect of Stra13, at least in part by abrogating its ability to inhibit
cyclin D1 expression.
Post-translational modifications play a significant role in the
regulation of transcription factors. Co-regulator proteins can
either promote or inhibit these modifications. SUMO modifi-
cation of many transcription factors appears to correlate with
transcriptional repression, which may reflect altered protein-
protein interactions. For instance, association with co-repressors
such as HDACs is generally enhanced by sumoylation, and
conversely interaction with co-activators is reduced [30,33].
Consistent with altered recruitment of co-regulators, sumoylated
Stra13 efficiently interacted with HDAC1, whereas the sumoy-
lation defective mutant Stra13 2KR exhibited reduced associ-
ation. HDACs enhance sumoylation of target proteins such as
MEF2 and HIC1 that may occur via deacetylation of lysine
residues, allowing them to be subsequently modified by
sumoylation [34,35]. Intriguingly however, HDAC1 inhibits
Stra13 sumoylation and its ability to repress cyclin D1 thereby
countering its anti-proliferative impact in fibroblast cells.
HDAC1-mediated inhibition of Stra13 sumoylation and cyclin
D1 repression is consistent with the opposing functions of the
two proteins in cellular proliferation. Stra13 has been reported
to repress cyclin D1 levels that correlate with its ability to
mediate G1 arrest and cause growth suppression. In contrast,
HDAC1 and HDAC2 promote cellular proliferation and cell
cycle progression by inhibiting the cyclin dependent kinases
(CDK) p21WAF1/CIP1 and p57Kip2 through direct regulation of
their promoters resulting in transcriptional repression [36,37].
Correspondingly, mouse embryonic fibroblasts lacking HDAC1
and HDAC2 are arrested in G1, and express elevated levels
p21WAF1/CIP1 and p57Kip2. Moreover, increased expression of
HDACs has been found in several cancers confirming their
roles in cellular proliferation [38,39]. Our studies suggest that in
addition to direct regulation of CDK levels, HDAC1 may
indirectly enhance proliferation by blocking growth suppressive
signals via desumoylation of Stra13 relieving repression of cyclin
D1. Given the impact of HDAC1 activity on Stra13 sumoyla-
tion, it is conceivable that in cells that overexpress both
Figure 2. Mutation of sumoylation sites abrogates Stra13-mediated growth suppression. (A) NIH3T3 cells were co-transfected with Stra13
or Stra13 2KR together with a puromycin resistance plasmid. Empty vector (pCS2) was transfected in control cells (Vector). Stra13 expression was
determined by western blotting using anti-Myc antibody. (B–C) Colony forming assays were performed with control, Stra13 and Stra13 2KR cells.
Colonies were stained with crystal violet 14 days later. Data are representative of three independent experiments (B). Crystal violet dye was extracted
and the absorbance measured at a wavelength of 570 nm. The error bars indicate standard deviations for triplicate wells in each experiment (C). (D)
Growth of NIH3T3 cells expressing vector alone, Stra13 and Stra13 2KR was evaluated over a five-day period. Cell numbers at each time are
represented as mean 6SD. (E) Stra132/2 MEFs were transfected at passage 5 with equivalent amounts of Stra13 and Stra13 2KR. Cell viability was
measured three days later by MTT assays. (F) Cell cycle profile of control (Vector), Stra13 and Stra132KR cells was determined by PI staining and FACS
analysis. Representative histograms of cell cycle profiles in cells expressing vector alone, Stra13 and Stra13 2KR. The result shown is representative of
three independent experiments.
doi:10.1371/journal.pone.0043137.g002
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proteins, Stra13 may exist in a desumoylated state, and unable
to block cellular proliferation allowing cells to bypass its growth
suppressive function. The mechanism by which HDAC1 inhibits
Stra13 sumoylation remains to be investigated. Since TSA can
antagonize the effect of HDAC1 on Stra13 sumoylation,
endogenous deacetylase activity is involved and may reflect a
requirement for acetylation-dependent sumoylation similar to
PML [40]. Alternatively, histone deacetylation by HDAC1 may
release promoter bound sumoylated Stra13, which could then
become accessible for desumoylation. Nonetheless, our studies
demonstrate sumoylation is an important mechanism by which
Stra13 transcriptional activity and function is modulated. Such
post-translational modifications may underlie the seemingly
paradoxical functions of Stra13 to either promote or inhibit
cellular differentiation and growth in different contexts.
Materials and Methods
Plasmids, Mutagenesis, and HDAC1 siRNA
Flag-mPIAS1, Flag-mPIAS3, Flag-mPIASxa, Flag-mPIASy,
SUMO1, SENP1, Flag-HDAC1, and pD1luc harboring the cyclin
D1 promoter have been described [4,31,41]. pCS2-Myc-Stra13
was derived from pCS2-Flag-Stra13 by PCR using primers 59-
GAA TTC ATG GAG CAG AAA CTC ATC TCT GAA GAG
GAT CTG GAA CGG ATC CCC AGC GCG-39 and 59-GAA
TTC TTA GTC TTT GGT TTC TAA GTT-39. The PCR
product was TA-cloned into pCRII (Invitrogen), and then
subcloned into the EcoR1 site of pCS2. K279R, K159R, and
2KR mutants were generated from pCS2-Myc-Stra13 using the
QuickChangeTM site-directed mutagenesis kit (Stratagene). Prim-
ers used for generating Stra13K279R are: 59-GTC AGC ACA
ATT AGG CAA GAA TCC GAA-39 and 59-TTC GGA TTC
TTG CCT AAT TGT GCT GAC-39; and for generating Stra13
K159R are: 59-CAG TAC CTG GCG AGG CAT GAG AAC
ACT-39 and 59-AGT GTT CTC ATG CCT CGC CAG GTA
CTG-39. The entire cDNA was sequenced to confirm the presence
of directed mutations. For HDAC1 knockdown, NIH3T3 cells
were transfected with 100 nM siRNA specific for mouse HDAC1
(Ambion); or with control scrambled siRNA using Lipofectamine
RNAiMAX (Invitrogen). The efficiency of knockdown was
determined using anti-HDAC1 antibody.
Cell Culture and Transient Transfections
HEK293 cells, COS-7 cells NIH3T3 and cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (HEK293), 10% calf serum (COS-7) and
10% bovine serum (NIH3T3) respectively. MEFs were cultured as
described [5]. Transfections were performed using Lipofectamine
Plus reagent according to the manufacturer’s instructions (Invitro-
gen).
Figure 3. Sumoylation is essential for Stra13-dependent growth inhibition. (A) Lysates of NIH3T3 cells transfected with Myc-Stra13, Stra13
2KR and SENP1 were immunoblotted with anti-Myc antibody. (B–C) After selection, colony assays were performed and colonies were stained with
crystal violet. Representative plates are shown (B). The mean relative absorbance after extraction of crystal violet stain from plates in shown in C. Error
bars indicate mean 6SD.
doi:10.1371/journal.pone.0043137.g003
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Immunoprecipitation and Western Blot Analysis
Cells were washed twice in cold PBS, lysed in 50 mM Tris-
HCl pH 8.0, 50 mM NaC1, 1 mM EDTA, 0.1% Triton X-100,
0.5 mM PMSF and protease inhibitors (Roche). To detect
sumoylation, 20 mM N-ethylmaleimide (Sigma) was added to
lysis buffer. Protein concentrations were determined by the
Bradford method (BioRad). Equal amounts of total protein were
loaded for western blotting. Lysates were incubated with Myc-
agarose beads (Sigma) in pull down buffer (as described above),
and precipitates analyzed by western blotting using the following
antibodies: anti-SUMO1 (1:200 Zymed), anti-Flag (1:5000
Sigma), anti-Myc (1:2000 Roche) and anti-b-actin (1:10,000
Sigma). For endogenous IP, 1.5 mg lysate was immunoprecip-
itated with 2 mg anti-Stra13 antibody (Bethyl Laboratories and
Novus Laboratories), and immunoblotted with anti-SUMO1
antibody and anti-HDAC1 antibody respectively (Upstate).
Proliferation, Cell Cycle Analysis, and Colony Suppression
Assays
NIH3T3 cells or MEFs were transfected with Stra13 or Stra13
2KR with pD503 that confers resistance to puromycin. Control
cells were transfected with empty vector and pD503. 24 hours (hr)
after transfection, cells were selected with 1.2 mg/ml puromycin
for three days. Selected cells were used for the following assays:
Proliferation/Viability assays. Cells were seeded at 16104
per well in 6-well plates in triplicates. Attached cells were
trypsinized and proliferation was measured by counting cells daily
over a period of five days. Alternatively, 3000 cells were seeded in
96-well plates and 72 hr later, MTT assays were performed using
MTT cell proliferation assay kit (Invitrogen).
Cell cycle. Selected cells were seeded at a density of 56105/
10-cm plates. 24 hr later, cells were fixed with cold 70% ethanol.
Twenty thousand cells were acquired and analyzed for DNA
content by propidium iodide staining (50 mg/ml) as described
previously [4,42]. Cell cycle distribution was analyzed by flow
cytometer (Becton Dickinson) using WINMDI software.
Figure 4. Sumoylation regulates Stra13 transcriptional activity but not its subcellular localization. (A) mRNA levels of cyclin D1, p21Cip/
WAF, cyclin B1, and cyclin E1 were analyzed by Q-PCR in vector, Stra13 and Stra13 2KR cells. (B) Cells were transfected with the cyclin D1 promoter
reporter pD1luc (100 ng) together with Stra13 (25 ng), Stra13 2KR (25 ng), SUMO1 (25 ng) or SENP1 (25 ng), as indicated. Cells were harvested 48 hr
after transfection, and assayed for luciferase activity. (C) COS-7 cells were transfected with Stra13 and Stra13 2KR alone or together with SUMO1. Cells
were stained with anti-Myc antibody. Nuclei were stained with DAPI. Error bars indicate mean 6SD. (D) NIH3T3 cells were left untreated or treated
with TSA. ChIP assays were done to determine Stra13 occupancy on the cyclin D1 promoter.
doi:10.1371/journal.pone.0043137.g004
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Colony suppression assays. Colony assays were done as
described [4,42]. Briefly cells were seeded at 16103/10-cm plate.
Two weeks later, colonies were fixed with 70% ethanol stained
with 0.02% crystal violet and photographed. For quantification,
the dye was extracted in 1% SDS and the absorbance read at
570 nm.
Chromatin immunoprecipitation (ChIP) assays. ChIP
assays were performed as described [43] using 3 mg of anti-Stra13
(Bethyl Laboratories) antibody. The following primers were used
for amplification of the cyclin D1 promoter: 59-GAGAGCT-
TAGGGCTCGTCTG-39 and 59-TGGGTGCGTTTCCGAG-
TAC-39; and for b-actin promoter: 59-
GCTTCTTTGCAGCTCCTTCGTTG-39 and 59-TTTGCA-
CATGCCGGAGCCGTTGT-39.
Quantitative RT-PCR (Q-PCR). Selected cells were syn-
chronized in mitosis by adding nocodazole at a final concentration
of 500 ng/ml. After 16 hr, nocodazole was removed by washing
with media. Total RNA was extracted from cells using TRIZOL
according to the manufacturer’s instructions (Invitrogen). Geno-
mic DNA was eliminated by treatment with TURBO DNase
(Ambion) and cDNA synthesis was carried out using AMV
Reverse Transcriptase (Promega) according to manufacturer’s
instructions. Q-PCR was performed using Light cycler 480 SYBR
green I master (Roche) as described [43]. The following primers
were used: Cyclin D1, 59-AAGTGCGTGCAGAAGGA-
GATTGTG-39 and 59-TCGGGCCGGATAGAGTTGTCAGT-
39; p21, 59-GCAGCCGAGAGGTGTGAGC-39 and 59-ACGG-
GACCGAAGAGACAACG-39; cyclin B1, 59-CGGTGAATG-
GACACCAACTCTG-39 and 59-CTGTGCCAGCGTGCT-
GATCT-39; cyclin E1, 59-
TGTCCTCGCTGCTTCTGCTTTGTATCAT-39 and 59-
GGCTTTCTTTGCTTGGGCTTTGTCC-39; and GAPDH:
59- ATCAACCGGGAAGCCCATCAC-39 and 59-
CCTTTTGGCTCCACCCTTCA-39.
Luciferase Assays
Cells were transfected with the cyclin D1 promoter reporter
pD1luc, Stra13, Stra13 2KR, SUMO1, SENP1 as indicated in the
figures along with 5 ng of Renilla luciferase. Empty expression
vector was added to normalize the amount of total DNA. 48 hr
after transfection, luciferase activity was measured by the Dual-
Luciferase Reporter Assay system (Promega). All transfections
were performed in triplicates, and repeated at least twice.
Immunofluorescence
COS-7 cells were used to examine subcellular localization of
Stra13 and Stra13 2KR. 48 hr after transfection, cells were fixed
in 4% formaldehyde, incubated with anti-Myc antibody and
detected with secondary antibody coupled with Texas-red
(Invitrogen). Slides were mounted in Vectashield (Vector Labora-
tories) supplemented with DAPI (49, 69-diamidino-2-phenylindole)
to identify nuclei. Cells were visualized on a Zeiss LSM 510
META confocal laser-scanning microscope.
Statistical Analysis
Error bars indicate mean6 standard deviation (S.D.). Statistical
analysis was performed with by Student’s t-test and P values,0.05
were considered statistically significant [*p,0.05; **p,0.01].
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